What is Curis?
Headquartered in Lexington, Curis, Inc. operates as a specialized biotechnology firm dedicated to the discovery and development of innovative drug candidates for oncology. The company's portfolio is anchored by a diverse array of small molecule inhibitors, including CUDC-907 and CA-4948, which target critical pathways in hematologic cancers and solid tumors. By maintaining strategic collaboration agreements with industry leaders such as F. Hoffmann-La Roche Ltd. and Aurigene Discovery Technologies, Curis effectively bridges the gap between laboratory-based research and commercial-scale therapeutic application. Its market position is defined by a rigorous focus on precision oncology, positioning the firm as a key player in the development of next-generation cancer treatments.
How much funding has Curis raised?
Curis has raised a total of $153.3M across 6 funding rounds:
Corporate Investment
$8M
Debt
$30M
Stock Offering
$64.7M
Share Placement
$30M
Debt
$350K
Private Equity
$20.2M
Corporate Investment (2010): $8M with participation from Debiopharm
Debt (2012): $30M led by Pharmakon Advisors
Stock Issuance/Offering (2015): $64.7M supported by Undisclosed
Share Placement (2020): $30M featuring Aspire Capital Limited
Debt (2020): $350K backed by PPP
Private Equity (2026): $20.2M with participation from Nantahala Capital Management and Stonepine Capital Management
Key Investors in Curis
Nantahala Capital Management
A fundamentally-driven alternative investment firm specializing in micro-cap stocks with a multi-year horizon and a focus on long-term growth.
Stonepine Capital Management
An investment management firm dedicated to the life sciences sector, providing strategic guidance and capital to biotechnology companies.
Debiopharm
The investment division of the Debiopharm Group, focused on safeguarding capital and generating consistent returns through private equity and strategic financial management.
What's next for Curis?
With the recent capital infusion, Curis is well-positioned to accelerate its Phase I and Phase II clinical trial programs. The strategic allocation of these funds will likely prioritize the advancement of its lead candidates through the regulatory pipeline, while simultaneously supporting the preclinical development of its newer small molecule assets. As the company moves forward, the focus remains on achieving key clinical milestones that validate the efficacy of its proprietary drug discovery platform. Investors and stakeholders will be closely monitoring the progression of these trials, as successful data readouts are expected to significantly enhance the company's valuation and strengthen its competitive standing within the global biopharmaceutical market.
See full Curis company page
